BeiGene slides on Shang­hai de­but as US preps to black­list some Chi­nese biotechs

Though it’s al­ready pub­licly trad­ed in the US and Hong Kong, BeiGene went and triple-list­ed it­self in Shang­hai’s stock ex­change as well. But ear­ly re­turns …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.